Biotech News
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
ir.pliantrx.com2026-05-06 14:53 EST
Oncology program advancing with data expected in the fourth quarter 2025 BEACON-IPF close out activities to be completed in the fourth quarter 2025 SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused